Mar. 26 at 11:32 PM
It was 1 year ago today
$SLNO got approval for Vykat.
SLNO's multiples suggest SLNO is severely undervalued if, and this is a GARGANTUAN if, but if analyst consensus revenue estimates are credible.
For perspective, the attachment compares SLNO 7-year analyst consenses to the 7 year revenue forecasts prepared by the mgmt/BOD of 10 peer commercial-stage bios acquired within 15 months of FDA approval.
Note analysts forecast SLNO to generate more revenues over the next 7 years than RETA mgmt/BOD forecast when
$RETA was acquired for an enterprise value of ~
$7.0B. RETA mgmt/BOD projected 91% gross margins where SLNO FY25 gross margin was 98%.
By itself, does this not suggest SLNO is deeply undervalued. Recall
$DAWN traded for virtually no enterprise value last summer & was just acquired for over
$2B
This is not investment advice. We do not understand Vykat's clinical value proposition, risk nor whether it's worth peer multiples.
$XBI $IBB